Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test

NCT ID NCT07595237

Recruiting now Disease control Sponsor: SmartNuclide Biopharma Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 20, 2026

Summary

This early-phase study tests a new radioactive drug (177Lu-DOTA-SNA040) in 12 people with advanced stomach, pancreatic, or bile duct cancers that have a specific marker (Claudin 18.2) and have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the drug spreads in the body. It is too early to know if the drug works, but researchers hope it will deliver radiation directly to cancer cells while sparing healthy tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS (SUCH AS GASTRIC CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS (SUCH AS ADENOCARCINOMA AT THE GASTROESOPHAGEAL JUNCTION) ADVANCED SOLID TUMORS (SUCH AS CHOLANGIOCARCINOMA) ADVANCED SOLID TUMORS (SUCH AS GASTRIC CANCER) ADVANCED SOLID TUMORS (SUCH AS PANCREATIC CANCER)